Sinclair Pharma and Invida Holdings Pvt. Ltd. have expanded their collaboration to include India in their long-term partnership for the commercialization of Sinclair’s dermatology brands in the Asia-Pacific region. Invida is a specialty biopharmaceutical company with 4,000 employees and a presence in all major markets, including India. The expanded collaboration now includes 12 markets within the Asia Pacific region under which Invida has exclusivity for Sinclair’s dermatology and wound care brands.

The Sinclair-Invida partnership is preparing for the commercialization phase for the initial launches. In India, Invida’s resources will be focused primarily on commercializing Sinclair’s products for atopic dermatitis, seborrhoeic dermatitis and acne. Invida’s team in India will be supported by Sinclair’s locally based regional business director to help ensure the timelines and success of these launches.

Chris Spooner, chief executive officer of Sinclair, said, “As a leading emerging market with the potential for sustainable high growth, India is key for Sinclair and Invida has again proved the compelling partner of choice with its demonstrable ambition, presence and commitment to our portfolio.”

John Graham, chief executive officer of Invida, said, ”I am delighted to expand our regional collaboration with Sinclair in India. This addition demonstrates the high confidence Sinclair has in Invida’s market expertise in India and throughout the region.”